Anagenics Limited · ASX:AN1

Anagenics — Cellmid — Investor Presentation (May 2021)

22 slides from Anagenics's investor presentation, May 3, 2021

  1. Slide 1: ASX Announcement: Investor Briefing and Presentation

    ASX ANNOUNCEMENT INVESTOR BIEFING AND PRESENTATION SYDNEY, Monday, 3 May 2021: Cellmid Limited (ASX: CDY) (“Company”) is pleased to invite investors to attend an online investor briefing on the Company’s growth strategy and the Lyramid divestment. As previously advised the briefing will be held toda

  2. Slide 2: Investor Presentation

    Investor Presentation 3 May 2021 ASX: CDY 1

  3. Slide 3: Forward looking statements

    Forward looking statements This presentation has been prepared by Cellmid Limited ACN 111 304 119 (CDY) for information purposes only. The presentation may contain forward-looking statements that are not guarantees of future performance and are subject to risks and uncertainties. Such forward lookin

  4. Slide 4: A health and beauty-tech business

    A health and beauty-tech business growing shareholder value through the global distribution and sales of its scientifically validated innovative consumer products to help people live longer, in good health and with confidence AGENDA • Well funded to execute growth strategy • Lyramid sale – completed

  5. Slide 5: Well-funded to execute on growth strategy

    WELL-FUNDED TO EXECUTE ON GROWTH STRATEGY Record cash balance of $8.8m to execute on growth strategy On track to profitability in FY2022 Strongly supported capital raising • Raised $4.5 million in an underwritten rights issue in March 2021 • Funds to boost ecommerce capabilities, provide cashflow fo

  6. Slide 6: Lyramid – completion of strategic milestone

    LYRAMID – COMPLETION OF STRATEGIC MILESTONE Completed the sale of Lyramid, Cellmid’s wholly owned biotech subsidiary Enables Cellmid to focus solely on consumer health business Key Terms of the Share Sale Agreement • Issued shares in Lyramid are sold to investors committed to funding the midkine pro

  7. Slide 7: Building a global beauty-tech business

    BUILDING A GLOBAL BEAUTY-TECH BUSINESS 6

  8. Slide 8: Focus on building innovative beauty brands

    FOCUS ON BUILDING INNOVATIVE BEAUTY BRANDS Maintain leadership in hair biology through ongoing research and publications and new intellectual property Grow product portfolio, launch anti-aging products with scientific evidence of efficacy Launch only first in class and/or best in class clinically va

  9. Slide 9: Anti-aging hair care products

    ANTI-AGING HAIR CARE PRODUCTS Cellmid developed proprietary anti-aging haircare products that are clinically and scientifically validated, effective in reducing hair loss and increasing hair growth, and use botanical extracts. • ‘First in class’ and ‘best in class’ clinically validated anti-aging ha

  10. Slide 10: COVID-19 disruption halted retail momentum

    COVID-19 DISRUPTION HALTED RETAIL MOMENTUM FY2016 - FY2019 - Strong revenue growth COVID-19 disruption to retail and supply • Expansion of distribution channels across Japan, China, Revenue $m chains US, Australia, Asia and Europe • Prestige positioning of évolis® in the US 8 +1% • Secured national

  11. Slide 11: Focused on most profitable distribution channels

    FOCUSED ON MOST PROFITABLE DISTRIBUTION CHANNELS Japan ecommerce New retail Export QVC Japan Barbershops Jo-Ju® and channels ecomm évolis® sales to Lexilis® (LOFT) China AU Priceline and ecommerc openshop Hair online Export to other e évolis® TV Salons retailers Europe pharmacy shopping USA Dermstor

  12. Slide 12: Growth strategy

    GROWTH STRATEGY 11

  13. Slide 13: Growth strategy: FY2021 to FY2023

    GROWTH STRATEGY: FY2021 to FY2023 1. GROW 2. ACHIEVE 3. FOCUS ON REVENUE PROFITABILITY BRAND Focus on product Grow recurring revenue Optimise deployment of innovation leveraging through Chinese capital by focusing on expertise in hair and distribution strong cashflow systems biology; agreements, gen

  14. Slide 14: Grow revenue: two Chinese distribution agreements

    GROW REVENUE: TWO CHINESE DISTRIBUTION AGREEMENTS Ourui Health Management Aeon International (Aeon) (OHM) Key Terms: Key Terms: • Renegotiated in 1H FY2021 • Signed in December 2020 for for distribution of évolis® distribution of Jo-Ju® and Lexilis® pharmacy products • Ten-year agreement • évolis® T

  15. Slide 15: Grow recurring revenue: ecommerce

    GROW RECURRING REVENUE: ECOMMERCE 2. Maintain portfolio of high performing PRODUCT PERFORMANCE IS THE products to nurture customer KEY TO SUBSCRIPTIONS trust and loyalty AND REPEAT CUSTOMERS • Ecommerce performance indicators 1. Build customer 3. Build direct database by relationship • Total online

  16. Slide 16: Grow revenue: B2B partnerships

    GROW REVENUE: B2B PARTNERHSIPS • Cellmid have been investing in its own e-commerce infrastructure and digital marketing capabilities while concurrently building distribution partnerships with online retailers • This mixed model has been an important strategy to build the online business cost effecti

  17. Slide 17: Achieve profitability

    ACHIEVE PROFITABILITY Optimise capital Continue to improve Take advantage of deployment supply chain economies of scale • Invest in opportunities • More strategic • Continue to explore with strong cash ingredient sourcing to opportunities for large generating potential improve cost of goods scale so

  18. Slide 18: Focus on new product development

    FOCUS ON NEW PRODUCT DEVELOPMENT Hair Skin Body • Differentiated skin care • Masstige FGF5 inhibitor • Anti-aging range with novel products supplements including technology • Improved scalp lotions proprietary ingredients • Reduce fine lines and • Volumizing, sulphate • Range of differentiated plump

  19. Slide 19: Financial overview and outlook

    FINANCIAL OVERVIEW AND OUTLOOK 18

  20. Slide 20: Q3 FY2021 – key highlights

    Q3 FY2021– KEY HIGHLIGHTS AUD$M Q3 FY2021 Q3 FY2020 • Underwritten rights issue raising $4.5 million (before costs) • Well-funded to execute growth strategy Cash balance 8.8* 3.0 • Q3 sales up on pcp Net operating cashflow (0.15) (0.90) Consumer Health Revenue 958K 858K • Received first order from e

  21. Slide 21: Upcoming milestones

    UPCOMING MILESTONES Expand in China: Increase market penetration and sales in China through cross border ecommerce, social commerce and the recently issued import permits for Jo-Ju and Lexilis shampoos USA and Australia sales growth: Through existing channels (Priceline, Amazon, Dermstore, Tru Beaut

  22. Slide 22: Thank you

    THANK YOU Maria Halasz CEO info@cellmid.com.au +61 9221 6830 21

Cellmid — Investor Presentation (May 2021) on 6ix